Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Ecallantide

Nature Reviews Drug Discovery volume 9, pages 189–190 (2010)Cite this article

Subjects

Abstract

In December 2009, ecallantide (Kalbitor; Dyax) — a recombinant protein inhibitor of plasma kallikrein — was approved by the US FDA for the treatment of acute attacks of hereditary angioedema.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Pathogenesis of hereditary angioedema and therapeutic interventions.

References

  1. Davis, A. E. 3rd. New treatments addressing the pathophysiology of hereditary angioedema. Clin. Mol. Allergy 6, 2 (2008).

    Article  Google Scholar 

  2. Schneider, L. et al. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J. Allergy Clin. Immunol. 120, 416–422 (2007).

    Article  CAS  Google Scholar 

  3. Bork, K., Yasothan, U & Kirkpatrick, P. Icatibant. Nature Rev. Drug Discov. 7, 801–802 (2008).

    Article  CAS  Google Scholar 

  4. Nussberger, J. et al. Plasma bradykinin in angio-oedema. Lancet 351, 1693–1697 (1998).

    Article  CAS  Google Scholar 

  5. US Food and Drug Administration. FDA labelling information — Kalbitor (ecallantide). FDA website [online], (2009).

  6. Ley, A. C. et al. Obtaining a family of high-affinity, high-specificity protein inhibitors of plasmin and plasma kallikrein. Mol. Divers. 2, 119–124 (1996).

    Article  CAS  Google Scholar 

  7. Markland, W. et al. Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin. Biochemistry 35, 8058–8067 (1996).

    Article  CAS  Google Scholar 

  8. IMS MIDAS (IMS Health, 2009).

  9. Nadeau, P. et al. SG Cowen Biotechnology Report (6 Jan 2010).

    Google Scholar 

  10. Monane, M. et al. Needham Investment Analysis (2 Dec 2009).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bruce Zuraw is at the Allergy and Immunology Section, University of California, San Diego School of Medicine, 9500 Gilman Drive, La Jolla, California 92037-0635, USA. bzuraw@ucsd.edu,

    Bruce Zuraw

  2. Uma Yasothan is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK. UYasothan@de.imshealth.com,

    Uma Yasothan

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. p.kirkpatrick@nature.com,

    Peter Kirkpatrick

Authors
  1. Bruce Zuraw
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Uma Yasothan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

B.Z. has participated in research with Lev Pharmaceuticals and Pharming AG, and has been a paid consultant for Dyax Inc., Jerini, Shire, CSL Behring and ViroPharma.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zuraw, B., Yasothan, U. & Kirkpatrick, P. Ecallantide. Nat Rev Drug Discov 9, 189–190 (2010). https://doi.org/10.1038/nrd3125

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3125

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research